News

KeyPlants Ships First-of-its-Kind Vaccine Manufacturing Facility to Africa

March 31, 2022

KeyPlants has shipped a first-of-its-kind vaccine manufacturing facility to Senegal in West Africa.

Sanofi and IGM Biosciences Announce Collaboration Agreement

March 31, 2022

Sanofi and IGM Biosciences have announced a collaboration agreement for oncology, immunology, and inflammation targets.

Patent Rights Battles Escalate as Debate over Drug Costs and Access Drags On

March 31, 2022

Consumer advocates continue to press for initiatives to lower drug prices by revising or reducing patent protections.

Pfizer Issues Voluntary Recall of Blood Pressure Tablets Due to High Levels of Nitrosamine

March 30, 2022

Pfizer has issued a voluntary nationwide recall on lots of Accuretic tablets due to high levels of nitrosamine.

Novavax and Serum Institute of India Announce Emergency Use Authorization of Novavax’ COVID-19 Vaccine in Adolescents Ages 12 to 18 in India

March 30, 2022

Novavax’ COVID-19 vaccine has been granted emergency use authorization for use in the adolescent population ages 12–18 in India.

Novartis’ Pluvicto Approved by FDA for Treatment of Advanced Prostate Cancer

March 30, 2022

FDA has approved Novartis’ targeted radioligand therapy Pluvicto for the treatment of progressive PSMA-positive metastatic castration-resistant prostate cancer.

Orion to Refocus R&D to Cancer and Pain

March 29, 2022

Orion is planning to refocus its R&D efforts on the development of new proprietary products focused on cancer and pain.

EMA Recommends EU Approval of Roche’s Polivy Combination for Diffuse Large B-Cell Lymphoma

March 29, 2022

EMA has recommended the approval of Roche’s Polivy plus R-CHP for the treatment of previously untreated diffuse large B-cell lymphoma in the EU.

Empagliflozin Trial Stopped Early Due to Clear Positive Efficacy in People with Chronic Kidney Disease

March 25, 2022

Boehringer Ingelheim announced Empagliflozin Phase III EMPA_KIDNEY trial will stop early due to clear positive efficacy in people with chronic kidney disease.

Huma and AstraZeneca Partner to Accelerate Innovation for Digital-First Patient Care

March 25, 2022

Huma has acquired AstraZeneca’s digital health platform, and AstraZeneca has become a shareholder of Huma in a partnership to accelerate digital-first patient care.